Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum Disorder / Sarah A. KEIM in Journal of Autism and Developmental Disorders, 52-12 (December 2022)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 52-12 (December 2022) . - p.5342-5355 Titre : Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum Disorder Type de document : texte imprimé Auteurs : Sarah A. KEIM, Auteur ; Abigail JUDE, Auteur ; Katie SMITH, Auteur ; Aiman Q. KHAN, Auteur ; Daniel L. COURY, Auteur ; Joseph RAUSCH, Auteur ; Shivika UDAIPURIA, Auteur ; Megan NORRIS, Auteur ; Lindsay R. BARTRAM, Auteur ; Anita R. NARAYANAN, Auteur ; Lynette K. ROGERS, Auteur Année de publication : 2022 Article en page(s) : p.5342-5355 Langues : Anglais (eng) Mots-clés : Child  Child, Preschool  Humans  Autism Spectrum Disorder/drug therapy  Biomarkers  Dietary Supplements  Double-Blind Method  Fatty Acids, Omega-3/therapeutic use  Fatty Acids, Omega-6/therapeutic use  Interleukin-2/metabolism  Autism spectrum disorder  Il-2  Inflammation  Omega-3 fatty acids  Omega-6 fatty acids  Young child  the content of this article. The content is solely the responsibility of the  authors and does not necessarily represent the official views of the National  Institutes of Health. Nordic Naturals provided the investigational product at no  cost  and Welsh, Holme, & Clark Co., Inc. provided canola oil at no cost. Neither  the study sponsors nor product providers had a role in the study design  the  collection, analysis, and interpretation of data  writing of this report  or the  decision to submit the manuscript for publication. Index. décimale : PER Périodiques Résumé : This double-blind, randomized controlled trial, tested fatty acid (FA) supplementation in children (ages 2- < 6 years) recently diagnosed with Autism Spectrum Disorder (ASD). Participants received daily oral FA supplement containing omega-3 and omega-6 FA, or a placebo for 90 days based on participant weight. Erythrocyte FAs and the cytokines, IL-1ÃŽ2, IL-2, IFNÃŽ3, were measured in plasma obtained from serial blood collections. Treatment increased omega-3 and omega-6 FA levels (1.40 mol% for EPA and 1.62 mol% for DHA) and reduced IL-2 levels compared to placebo (- 0.17 pg/mL, 95% CI - 0.31, - 0.02, d=- 0.62). Omega 3-6 treatment was tolerable and adherence was greater than 70%. Future research will assess the effects of Omega 3-6 treatment on ASD symptoms. Registered on 06/08/2018 with ClinicalTrials.gov: NCT03550209. En ligne : http://dx.doi.org/10.1007/s10803-021-05396-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=489 [article] Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum Disorder [texte imprimé] / Sarah A. KEIM, Auteur ; Abigail JUDE, Auteur ; Katie SMITH, Auteur ; Aiman Q. KHAN, Auteur ; Daniel L. COURY, Auteur ; Joseph RAUSCH, Auteur ; Shivika UDAIPURIA, Auteur ; Megan NORRIS, Auteur ; Lindsay R. BARTRAM, Auteur ; Anita R. NARAYANAN, Auteur ; Lynette K. ROGERS, Auteur . - 2022 . - p.5342-5355. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 52-12 (December 2022) . - p.5342-5355 Mots-clés : Child  Child, Preschool  Humans  Autism Spectrum Disorder/drug therapy  Biomarkers  Dietary Supplements  Double-Blind Method  Fatty Acids, Omega-3/therapeutic use  Fatty Acids, Omega-6/therapeutic use  Interleukin-2/metabolism  Autism spectrum disorder  Il-2  Inflammation  Omega-3 fatty acids  Omega-6 fatty acids  Young child  the content of this article. The content is solely the responsibility of the  authors and does not necessarily represent the official views of the National  Institutes of Health. Nordic Naturals provided the investigational product at no  cost  and Welsh, Holme, & Clark Co., Inc. provided canola oil at no cost. Neither  the study sponsors nor product providers had a role in the study design  the  collection, analysis, and interpretation of data  writing of this report  or the  decision to submit the manuscript for publication. Index. décimale : PER Périodiques Résumé : This double-blind, randomized controlled trial, tested fatty acid (FA) supplementation in children (ages 2- < 6 years) recently diagnosed with Autism Spectrum Disorder (ASD). Participants received daily oral FA supplement containing omega-3 and omega-6 FA, or a placebo for 90 days based on participant weight. Erythrocyte FAs and the cytokines, IL-1ÃŽ2, IL-2, IFNÃŽ3, were measured in plasma obtained from serial blood collections. Treatment increased omega-3 and omega-6 FA levels (1.40 mol% for EPA and 1.62 mol% for DHA) and reduced IL-2 levels compared to placebo (- 0.17 pg/mL, 95% CI - 0.31, - 0.02, d=- 0.62). Omega 3-6 treatment was tolerable and adherence was greater than 70%. Future research will assess the effects of Omega 3-6 treatment on ASD symptoms. Registered on 06/08/2018 with ClinicalTrials.gov: NCT03550209. En ligne : http://dx.doi.org/10.1007/s10803-021-05396-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=489

---

1 (1 - 1 / 1) Par page : 25 50 100 200